Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified i...
Saved in:
| Published in | BMC psychiatry Vol. 10; no. 1; p. 43 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
10.06.2010
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI.
Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors.
Based on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further olanzapine LAI injections following the event. No clear risk factors were identified.
Post-injection delirium/sedation syndrome can be readily identified based on symptom presentation, progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper injection technique and a post-injection observation period.
ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489. |
|---|---|
| AbstractList | Abstract Background An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI. Methods Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors. Results Based on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further olanzapine LAI injections following the event. No clear risk factors were identified. Conclusions Post-injection delirium/sedation syndrome can be readily identified based on symptom presentation, progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper injection technique and a post-injection observation period. Trial Registration ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489. BACKGROUND: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI. METHODS: Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors. RESULTS: Based on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further olanzapine LAI injections following the event. No clear risk factors were identified. CONCLUSIONS: Post-injection delirium/sedation syndrome can be readily identified based on symptom presentation, progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper injection technique and a post-injection observation period. TRIAL REGISTRATION: ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489. An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI. Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors. Based on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further olanzapine LAI injections following the event. No clear risk factors were identified. Post-injection delirium/sedation syndrome can be readily identified based on symptom presentation, progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper injection technique and a post-injection observation period. ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489. An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI. Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors. Based on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further olanzapine LAI injections following the event. No clear risk factors were identified. Post-injection delirium/sedation syndrome can be readily identified based on symptom presentation, progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper injection technique and a post-injection observation period. ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489. Background An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI. Methods Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors. Results Based on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further olanzapine LAI injections following the event. No clear risk factors were identified. Conclusions Post-injection delirium/sedation syndrome can be readily identified based on symptom presentation, progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper injection technique and a post-injection observation period. Trial Registration ClinicalTrials.gov ID; URL: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI. Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors. Based on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further olanzapine LAI injections following the event. No clear risk factors were identified. Post-injection delirium/sedation syndrome can be readily identified based on symptom presentation, progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper injection technique and a post-injection observation period. An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI.BACKGROUNDAn advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI.Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors.METHODSSafety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors.Based on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further olanzapine LAI injections following the event. No clear risk factors were identified.RESULTSBased on approximately 45,000 olanzapine LAI injections given to 2054 patients in clinical trials through 14 October 2008, post-injection delirium/sedation syndrome occurred in approximately 0.07% of injections or 1.4% of patients (30 cases in 29 patients). Symptomatology was consistent with olanzapine overdose (e.g., sedation, confusion, slurred speech, altered gait, or unconsciousness). However, no clinically significant decreases in vital signs were observed. Symptom onset ranged from immediate to 3 to 5 hours post injection, with a median onset time of 25 minutes post injection. All patients recovered within 1.5 to 72 hours, and the majority continued to receive further olanzapine LAI injections following the event. No clear risk factors were identified.Post-injection delirium/sedation syndrome can be readily identified based on symptom presentation, progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper injection technique and a post-injection observation period.CONCLUSIONSPost-injection delirium/sedation syndrome can be readily identified based on symptom presentation, progression, and temporal relationship to the injection, and is consistent with olanzapine overdose following probable accidental intravascular injection of a portion of the olanzapine LAI dose. Although there is no specific antidote for olanzapine overdose, patients can be treated symptomatically as needed. Special precautions include use of proper injection technique and a post-injection observation period.ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489.TRIAL REGISTRATIONClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489. |
| ArticleNumber | 43 |
| Audience | Academic |
| Author | Zhao, Fangyi Stefaniak, Victoria J Brunner, Elizabeth Corya, Sara A Sorsaburu, Sebastian Detke, Holland C McDonnell, David P |
| AuthorAffiliation | 1 Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA |
| AuthorAffiliation_xml | – name: 1 Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA |
| Author_xml | – sequence: 1 givenname: Holland C surname: Detke fullname: Detke, Holland C – sequence: 2 givenname: David P surname: McDonnell fullname: McDonnell, David P – sequence: 3 givenname: Elizabeth surname: Brunner fullname: Brunner, Elizabeth – sequence: 4 givenname: Fangyi surname: Zhao fullname: Zhao, Fangyi – sequence: 5 givenname: Sebastian surname: Sorsaburu fullname: Sorsaburu, Sebastian – sequence: 6 givenname: Victoria J surname: Stefaniak fullname: Stefaniak, Victoria J – sequence: 7 givenname: Sara A surname: Corya fullname: Corya, Sara A |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20537128$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkktvEzEQx1eoiD7gzA1Z4sCl2_i5Dw5IbcUjUiU4gMTN8tqziaNdO9gbUPoZ-NB4syVqUCvkg62Z__zG8zjNjpx3kGUvCb4gpCpmhJckp5x_zwnOOXuSnewtR_fex9lpjCuMSVkJ8iw7pliwktDqJPv9xccht24FerDeIQOdDXbTzyIYtbPErTPB94CsQ-tkAjdE9MsOSxT10t769TKAswoNAdQAZnL5TrlbtbYOUOfdIleJ7hZon-cczd8i5VS3jTYi3yKtIsTn2dNWdRFe3N1n2bcP779ef8pvPn-cX1_e5I1ghOW6NbUhSmgjiDbG1EVDlGEVa3FTaEZ4C0bThkFRC6pLDqbSnCWRbkqhScPOsvnENV6t5DrYXoWt9MrKncGHhVRhsLoDWXNcFpUA0Bw4qUEVhNVGKE4F5aQQifVuYq03TZ_ypvYE1R1ADz3OLuXC_5S0qoWo6gS4mgCN9Y8ADj3a93KcrBwnKwmWnCXIm7tfBP9jA3GQvY0aujQG8JsoSy4Kzimp_q9krKAlwSPz9aRcqNQI61qf0utRLS8pw7QqMR7rv3hAlY6B3uq0ra1N9oOAV_cbti_0704mwWwS6OBjDNDuJanWcesfqF78E6HtsNve9BfbPRr3B7nJCJM |
| CitedBy_id | crossref_primary_10_3109_08039488_2013_852243 crossref_primary_10_36290_psy_2022_029 crossref_primary_10_1016_j_encep_2017_05_004 crossref_primary_10_1136_dtb_2012_08_0127 crossref_primary_10_1186_s12888_014_0298_4 crossref_primary_10_2147_PGPM_S391401 crossref_primary_10_1097_JCP_0000000000000509 crossref_primary_10_1016_j_jemermed_2013_08_118 crossref_primary_10_1177_0004867420927465 crossref_primary_10_61409_V12230776 crossref_primary_10_1007_s40263_014_0216_9 crossref_primary_10_1097_JCP_0000000000001847 crossref_primary_10_1517_14656566_2011_553193 crossref_primary_10_1039_c3ra41967c crossref_primary_10_3111_13696998_2013_823869 crossref_primary_10_1097_JCP_0000000000000358 crossref_primary_10_1111_bcpt_12394 crossref_primary_10_1111_j_1601_5215_2012_00670_x crossref_primary_10_1007_s40263_018_0508_6 crossref_primary_10_1016_S0034_7450_14_60074_3 crossref_primary_10_1192_bjp_2024_251 crossref_primary_10_1185_03007995_2012_657300 crossref_primary_10_1097_HRP_0b013e31827fd915 crossref_primary_10_1097_FTD_0000000000001317 crossref_primary_10_1517_14740338_2013_832753 crossref_primary_10_1080_14737175_2017_1371014 crossref_primary_10_1007_s00115_015_0021_9 crossref_primary_10_1097_JCP_0000000000001091 crossref_primary_10_1177_20451253221113093 crossref_primary_10_4045_tidsskr_13_0335 crossref_primary_10_1016_j_addr_2020_11_008 crossref_primary_10_1177_2045125312446395 crossref_primary_10_1186_s12888_015_0669_5 crossref_primary_10_1186_1471_244X_12_51 crossref_primary_10_1186_1471_244X_13_20 crossref_primary_10_1192_bjpo_bp_116_004382 crossref_primary_10_3109_13651501_2014_1000928 crossref_primary_10_1002_hup_1225 crossref_primary_10_1007_s40263_013_0083_9 crossref_primary_10_1177_2045125314531982 crossref_primary_10_1007_s13760_021_01707_0 crossref_primary_10_1097_YIC_0000000000000139 crossref_primary_10_9758_cpn_2021_19_3_434 crossref_primary_10_1017_S1092852913000783 crossref_primary_10_1097_WNF_0000000000000329 crossref_primary_10_3371_CSRP_GOAG_043013 crossref_primary_10_1208_s12248_022_00771_5 crossref_primary_10_3371_CSRP_HISU_020813 crossref_primary_10_1185_03007995_2013_835715 crossref_primary_10_1002_phar_1313 crossref_primary_10_1017_S1092852921000249 crossref_primary_10_3109_15622975_2012_739708 crossref_primary_10_1097_WNF_0b013e3182854f70 crossref_primary_10_1586_14737175_2013_811984 crossref_primary_10_1002_mpr_1443 crossref_primary_10_1097_JCP_0000000000001742 crossref_primary_10_1186_s12888_015_0450_9 crossref_primary_10_1007_s00115_024_01733_2 crossref_primary_10_1097_JCP_0000000000001073 crossref_primary_10_3389_fpsyt_2022_1028350 crossref_primary_10_1002_j_2055_2335_2011_tb00681_x crossref_primary_10_1177_0897190014562352 crossref_primary_10_1007_s00520_016_3075_8 crossref_primary_10_4137_JCNSD_S4091 crossref_primary_10_1517_14656566_2012_686169 crossref_primary_10_1517_14740338_2016_1141893 crossref_primary_10_1136_bcr_2016_214806 crossref_primary_10_1136_emermed_2024_213972 crossref_primary_10_1177_2045125316656319 crossref_primary_10_1186_1471_244X_10_45 crossref_primary_10_1186_1471_244X_14_7 crossref_primary_10_2217_npy_11_24 crossref_primary_10_23736_S2532_1285_23_00195_7 crossref_primary_10_4137_CMPsy_S6659 crossref_primary_10_1017_S1092852917000840 crossref_primary_10_1097_JCP_0000000000000140 |
| Cites_doi | 10.1097/01.alc.0000183011.86768.61 10.4088/JCP.v69n0512 10.1186/1471-244X-10-45 10.1176/appi.ajp.2009.07081221 10.2307/3464849 10.1097/00007435-197801000-00002 10.1016/S0025-6196(11)61533-4 10.7326/0003-4819-147-4-200708210-00021 10.1016/S0140-6736(67)91658-3 10.7748/ns1999.06.13.39.47.c2623 10.1038/sj.npp.1301409 10.2190/KNQT-UEU4-GAQ2-57L6 10.1136/bmj.2.5649.89 10.1111/j.1530-0277.1986.tb05167.x 10.1172/JCI105903 10.1016/S0924-977X(08)70638-2 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2010 BioMed Central Ltd. Copyright ©2010 Detke et al; licensee BioMed Central Ltd. 2010 Detke et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2010 BioMed Central Ltd. – notice: Copyright ©2010 Detke et al; licensee BioMed Central Ltd. 2010 Detke et al; licensee BioMed Central Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TK 5PM DOA |
| DOI | 10.1186/1471-244X-10-43 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitleList | MEDLINE Neurosciences Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-244X |
| EndPage | 43 |
| ExternalDocumentID | oai_doaj_org_article_9407685eec4e419ea6139d5a42524165 PMC2895589 oai_biomedcentral_com_1471_244X_10_43 A230287005 20537128 10_1186_1471_244X_10_43 |
| Genre | Meta-Analysis Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- 0R~ 23N 2VQ 2WC 4.4 53G 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C1A C6C CCPQU CITATION CS3 DIK DWQXO E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GNUQQ GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ IPY ITC KQ8 M1P M2M M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PSYQQ RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 7X8 7TK -A0 3V. ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 5PM PUEGO |
| ID | FETCH-LOGICAL-b5313-cfd9d1a5cd51cddd96b1ad383f0b6c314fedc2b3e6952c74ed8c436b1cb75c1b3 |
| IEDL.DBID | RBZ |
| ISSN | 1471-244X |
| IngestDate | Wed Aug 27 01:26:03 EDT 2025 Thu Aug 21 18:32:54 EDT 2025 Wed May 22 07:10:35 EDT 2024 Mon Jul 21 09:33:41 EDT 2025 Fri Jul 11 03:41:05 EDT 2025 Tue Jun 17 21:15:03 EDT 2025 Tue Jun 10 20:43:45 EDT 2025 Mon Jul 21 06:04:18 EDT 2025 Thu Apr 24 23:12:14 EDT 2025 Tue Jul 01 01:46:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b5313-cfd9d1a5cd51cddd96b1ad383f0b6c314fedc2b3e6952c74ed8c436b1cb75c1b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | http://dx.doi.org/10.1186/1471-244X-10-43 |
| PMID | 20537128 |
| PQID | 733627103 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9407685eec4e419ea6139d5a42524165 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2895589 biomedcentral_primary_oai_biomedcentral_com_1471_244X_10_43 proquest_miscellaneous_745644218 proquest_miscellaneous_733627103 gale_infotracmisc_A230287005 gale_infotracacademiconefile_A230287005 pubmed_primary_20537128 crossref_primary_10_1186_1471_244X_10_43 crossref_citationtrail_10_1186_1471_244X_10_43 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-06-10 |
| PublicationDateYYYYMMDD | 2010-06-10 |
| PublicationDate_xml | – month: 06 year: 2010 text: 2010-06-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | BMC psychiatry |
| PublicationTitleAlternate | BMC Psychiatry |
| PublicationYear | 2010 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | Institute for Safe Medication Practices (673_CR10) 2004 Electronic Medicines Compendium (673_CR4) 2009 J Lauriello (673_CR1) 2008; 69 D Mamo (673_CR17) 2008; 33 KJ Mukamal (673_CR23) 2005; 29 S Sen (673_CR14) 2005; 80 Institute for Safe Medication Practices (673_CR9) 1999 B Workman (673_CR28) 1999; 13 HJ Weis (673_CR22) 1968; 47 SC Beyea (673_CR27) 1996; 96 European Medicines Agency (673_CR3) 2008 M Do Carmo de Castro Miranda (673_CR11) 2004; 3 D Kurtz (673_CR16) 2008; 63 JL Cummings (673_CR7) 1986; 16 Institute for Safe Medication Practices (673_CR13) 2006 TF Downham (673_CR6) 1978; 5 DP McDonnell (673_CR5) 2010; 10 A Hart (673_CR25) 1969; 2 HG Goldsweig (673_CR20) 1976; 3 Institute for Safe Medication Practices (673_CR8) 1997 J Tang (673_CR15) 2007; 147 JM Kane (673_CR2) 2010; 167 HC Detke (673_CR19) 2008; 11 FL Iber (673_CR24) 1986; 10 H Detke (673_CR18) 2008; 18 Novocol Pharmaceuticals of Canada, Inc (673_CR12) 2005 HJ Weis (673_CR21) 1967; 2 KR Purushothaman (673_CR26) 2007; 45 3744684 - Int J Psychiatry Med. 1986-1987;16(2):163-8 4166411 - Lancet. 1967 Sep 2;2(7514):495-7 5775455 - Br Med J. 1969 Apr 12;2(5649):89-91 17443131 - Neuropsychopharmacology. 2008 Jan;33(2):298-304 17249333 - Indian J Exp Biol. 2007 Jan;45(1):93-102 20008947 - Am J Psychiatry. 2010 Feb;167(2):181-9 5675432 - J Clin Invest. 1968 Sep;47(9):2169-80 17709768 - Ann Intern Med. 2007 Aug 21;147(4):283-4 20537130 - BMC Psychiatry. 2010;10:45 15945530 - Mayo Clin Proc. 2005 Jun;80(6):783-95 1271387 - J Rheumatol. 1976 Mar;3(1):37-42 3544923 - Alcohol Clin Exp Res. 1986 Dec;10(6):679-81 417409 - Sex Transm Dis. 1978 Jan-Mar;5(1):4-9 8546185 - Am J Nurs. 1996 Jan;96(1):34-5 16269922 - Alcohol Clin Exp Res. 2005 Oct;29(10):1906-12 18452346 - J Clin Psychiatry. 2008 May;69(5):790-9 10497490 - Nurs Stand. 1999 Jun 16-22;13(39):47-53; quiz 54 |
| References_xml | – volume: 29 start-page: 1906 year: 2005 ident: 673_CR23 publication-title: Alcohol Clin Exp Res doi: 10.1097/01.alc.0000183011.86768.61 – volume: 69 start-page: 790 year: 2008 ident: 673_CR1 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v69n0512 – volume: 10 start-page: 45 year: 2010 ident: 673_CR5 publication-title: BMC Psychiatry doi: 10.1186/1471-244X-10-45 – volume: 167 start-page: 181 year: 2010 ident: 673_CR2 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2009.07081221 – volume: 96 start-page: 34 year: 1996 ident: 673_CR27 publication-title: Am J Nurs doi: 10.2307/3464849 – volume: 5 start-page: 4 year: 1978 ident: 673_CR6 publication-title: Sex Transm Dis doi: 10.1097/00007435-197801000-00002 – volume: 80 start-page: 783 year: 2005 ident: 673_CR14 publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(11)61533-4 – volume: 11 start-page: S151 issue: suppl 1 year: 2008 ident: 673_CR19 publication-title: International Journal of Neuropsychopharmacology – volume: 147 start-page: 283 year: 2007 ident: 673_CR15 publication-title: Ann Intern Med doi: 10.7326/0003-4819-147-4-200708210-00021 – volume-title: ISMP medication safety alert: Bicillin products: syringe enhancements may help to prevent IV administration year: 2004 ident: 673_CR10 – volume: 2 start-page: 495 year: 1967 ident: 673_CR21 publication-title: Lancet doi: 10.1016/S0140-6736(67)91658-3 – volume: 13 start-page: 47 year: 1999 ident: 673_CR28 publication-title: Nurs Stand doi: 10.7748/ns1999.06.13.39.47.c2623 – volume-title: ISMP medication safety alert: Many wrongly believe long-acting parenteral penicillins are for intravenous injection year: 1999 ident: 673_CR9 – volume: 33 start-page: 298 year: 2008 ident: 673_CR17 publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1301409 – volume: 3 start-page: 37 year: 1976 ident: 673_CR20 publication-title: J Rheumatol – volume-title: Summary of product characteristics for ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection year: 2009 ident: 673_CR4 – volume-title: ISMP medication safety alert: Action needed to prevent serious tissue injury with IV promethazine year: 2006 ident: 673_CR13 – volume-title: Septocaine with epinephrine [package insert] year: 2005 ident: 673_CR12 – volume: 45 start-page: 93 year: 2007 ident: 673_CR26 publication-title: Indian J Exp Biol – volume-title: ISMP medication safety alert: Hazard warning year: 1997 ident: 673_CR8 – volume: 63 start-page: 288S issue: suppl 1 year: 2008 ident: 673_CR16 publication-title: Biol Psychiatry – volume: 16 start-page: 163 year: 1986 ident: 673_CR7 publication-title: Int J Psychiatry Med doi: 10.2190/KNQT-UEU4-GAQ2-57L6 – volume: 2 start-page: 89 year: 1969 ident: 673_CR25 publication-title: Br Med J doi: 10.1136/bmj.2.5649.89 – volume: 10 start-page: 679 year: 1986 ident: 673_CR24 publication-title: Alcohol Clin Exp Res doi: 10.1111/j.1530-0277.1986.tb05167.x – volume-title: Assessment report for Zypadhera year: 2008 ident: 673_CR3 – volume: 47 start-page: 2169 year: 1968 ident: 673_CR22 publication-title: J Clin Invest doi: 10.1172/JCI105903 – volume: 18 start-page: S435 issue: suppl 4 year: 2008 ident: 673_CR18 publication-title: European Neuropsychopharmacology doi: 10.1016/S0924-977X(08)70638-2 – volume: 3 start-page: 253 year: 2004 ident: 673_CR11 publication-title: J Vasc Bras – reference: 17709768 - Ann Intern Med. 2007 Aug 21;147(4):283-4 – reference: 15945530 - Mayo Clin Proc. 2005 Jun;80(6):783-95 – reference: 8546185 - Am J Nurs. 1996 Jan;96(1):34-5 – reference: 17443131 - Neuropsychopharmacology. 2008 Jan;33(2):298-304 – reference: 18452346 - J Clin Psychiatry. 2008 May;69(5):790-9 – reference: 20537130 - BMC Psychiatry. 2010;10:45 – reference: 20008947 - Am J Psychiatry. 2010 Feb;167(2):181-9 – reference: 1271387 - J Rheumatol. 1976 Mar;3(1):37-42 – reference: 10497490 - Nurs Stand. 1999 Jun 16-22;13(39):47-53; quiz 54 – reference: 5775455 - Br Med J. 1969 Apr 12;2(5649):89-91 – reference: 417409 - Sex Transm Dis. 1978 Jan-Mar;5(1):4-9 – reference: 3544923 - Alcohol Clin Exp Res. 1986 Dec;10(6):679-81 – reference: 5675432 - J Clin Invest. 1968 Sep;47(9):2169-80 – reference: 4166411 - Lancet. 1967 Sep 2;2(7514):495-7 – reference: 17249333 - Indian J Exp Biol. 2007 Jan;45(1):93-102 – reference: 16269922 - Alcohol Clin Exp Res. 2005 Oct;29(10):1906-12 – reference: 3744684 - Int J Psychiatry Med. 1986-1987;16(2):163-8 |
| SSID | ssj0017851 |
| Score | 2.2435431 |
| SecondaryResourceType | review_article |
| Snippet | An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting... Background An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine... BACKGROUND: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine... Abstract Background An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as... |
| SourceID | doaj pubmedcentral biomedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 43 |
| SubjectTerms | Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Benzodiazepines - administration & dosage Benzodiazepines - adverse effects Benzodiazepines - therapeutic use Care and treatment Clinical Trials as Topic - statistics & numerical data Cognition Disorders Complications and side effects Delayed-Action Preparations Delirium Delirium - chemically induced Delirium - epidemiology Development and progression Dosage and administration Drug Administration Schedule Drug Overdose - epidemiology Drug Overdose - etiology Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - metabolism Humans Incidence Injections, Intramuscular Olanzapine Research article Risk Factors Schizophrenia Schizophrenia - diagnosis Schizophrenia - drug therapy Sleep - drug effects Syndrome Treatment Outcome |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9QwDI7QHhAXxJvCgnJAggNhpm2SpnBaEKsFaTmx0tyivLoUDZnVdufCb-BHY7fpaKIVcOFau0qT2LHd2J8JeQE-qnVq6ZgRsma8NpzZzipWcxFMU7pGBfwPefpFnpzxzyux2mv1hTlhEzzwtHCLluNdkQjB8cDLNhiwP60XBmQNjI8c0UvB5s3BVLo_wJbzY11RUzIwYKsE6lMqudg9wxMIi3WyQvd1Zp9GGP_rh_WetcozKfdM0_Edcjv5lPRomstdciPEe-Tmabo1v09-YUde1sfvY9pVpD6s-8t--2MxhKmjEp1xC2gfaUJaHSj-oqXDflIeHdPSg59IEBTHn-YChqDrTTxnWCIRz-lunNf001tqEugJ3XTUgcUcHpCz449fP5yw1IWBWdDPmrnOt740wnlROu99K21pPAS23dJKV5e8g-lXtg6yFZVrePDK8RqYnG2EK239kBzETQyPCZWN9HzJjZIQ9XHjrA8KwkUZlG2rypmCvMv2Ql9MiBsaMbBzCqijxp3UuJMaIhleF-TNvHPaJYBz7LOx1mOgo-T1F17tXphH-iPrexSF7IPGByCqOomq_peoFuQlCpLGowM-zJlUAQGLgyBc-gjCQbx3XgLnYcYJKu8yMp1FUSMJ8-Ri2GwHjeCWFTiN9V9YEECIg2dXkEeT8O5mVSG4DzgsBWkysc6mnVNi_23EJIe4XQjVPvkf6_SU3JpyNCSo6CE5uLrchmfg-l3Z56OW_wZDclbs priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF5BkRCXijeBgvaABAfcxt6HbRBCBVEVpHAiUm6rfTkYhXUbNxLwG_jRzNibNKYFcc2Ms97deXpnvyHkKcSoxhZjm2ghWcKZ5ompTJEwLrzOU5sXHr9DTj7J4yn_OBOz83ZAcQHbS1M77Cc1XS72v5_-eAMK_7pT-EIepGBgE3BTM7QpnF0l18At5ailE35-pIBd6LurRpE54vxc8gd_3H1fDFxWh-x_0X5vObBhceWWtzq6SXZjmEkPe7m4Ra74cJtcn8SD9DvkFzbpTerwtavECtT5Rb2sV98OWt83WaJrKANaBxrBV1uKX21pu12nR7tKde96Eixm-KlPYAi6aMI8wVsTYU4347ygH15SHXFQaFNRC060vUumR-8_vztOYmOGxIDKssRWrnSpFtaJ1DrnSmlS7SDXrcZGWpbyCqafGeZlKTKbc-8KyxkwWZMLmxp2j-yEJvgHhMpcOj7mupCQCHJtjfMFZJDSF6bMMqtH5NVgL9RJD8KhEBZ7SAENVbiTCndSQXLD2Yjsr3dO2Yh5jq03FqrLfQp58YHnmwfWI_2V9S2KwuCFuh-a5VxFtVclx5NO4b3lnqel1xA9lU5osJQgo1KMyDMUJIXyDS9mdbwUAYuDuFzqEDJEPIoeA-fegBOsgB2Q6VoUFZKwdC74ZtUqxLvMII5k_2BBTCEOwd6I3O-FdzOrDPF-IIYZkXwg1oNpDymh_tLBlEMqL0RRPvzvKT4iN_raDAl6uEd2zpYr_xhCvjPzpFPl36sXVkQ priority: 102 providerName: Scholars Portal |
| Title | Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20537128 https://www.proquest.com/docview/733627103 https://www.proquest.com/docview/745644218 http://dx.doi.org/10.1186/1471-244X-10-43 https://pubmed.ncbi.nlm.nih.gov/PMC2895589 https://doaj.org/article/9407685eec4e419ea6139d5a42524165 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF7RVkJcKt64lGgPSHDANPY-vIZTg1oVpFQIUSnistqXi1HYVHVz4Tfwo5mxnRC3wIVLDplx1pt5785-S8hzyFGtU2OXGiFZypnhqa2sShkXwRSZK1TAdcjpqTw54x9mYvYbLPraDn6m5EEG7jOFIDRDj8HZFtnJOYRBLMwnX9YbBnjHfHuQqGfuUXz-8APXTrbPBwGpxe2_6Z03wtOwdXIjFh3fJbt9EkkPO6nfI7dCvE9uT_tt8gfkJ17Bm9bxW9tnFakP8_qyXn4_aEJ3hRJdARXQOtIeWrWhuCZLm80uPNr2oQffkaAKjj_MBQxB54t4nuKZiHhO1-O8ou_fUNOjnNBFRR2EyOYhOTs--vzuJO2vXUgtGCRLXeVLnxnhvMic976UNjMeKtlqbKVjGa9g-rllQZYidwUPXjnOgMnZQrjMskdkOy5ieEKoLKTnY26UhDKPG2d9UFAfyqBsmefOJOTtQBb6ooPY0Ah6PaSA_WmUpEZJaihdOEvI65XktOsRzfFijbluKxslbz7wcv3AaqS_sk5QFQYv1H4Bqql7o9Ylx31MEYLjgWdlMJAblV4Y8IOQGEmRkBeoSBp9BbyYM_2RB_hzEHVLH0L9hxvNY-DcH3CCjbsBma5UUSMJG-NiWCwbjWiWOWSJ7B8siBjEIZVLyONOedezyhHNBzKUhBQDtR5Me0iJ9dcWhBwKdSFUufdfEnxK7nTdGBJsc59sX10uwzNI8q7siGwVs2JEdiZHpx8_jdqlEviccjVqDf8XABtVBg |
| linkProvider | BioMedCentral |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF6VIgEXxBtDgT0gwQG3sfdhG04tokqh6QG1UsRlta8Eo3RTJc2F38CPZsaPkKXAhatn7PV6ZmdnvDPfEPISfFRjy4FNtZAs5Uzz1ExMmTIuvC4yW5Qe_0OOTuTwjH8ci_EWGfa1MObc_krz3d0sQZ81drtPF2tXeyn3MrCuKexRYzQonF0j1wshCuxl8Pngy_o8AVvQN3VGHXMH8vOHB_xW-D6L9qsG1v-q8d7YveLMyo2t6vAOud35mHS_ncRdsuXDPXJj1J2i3yc_sENvWodvTRpWoM7P6kW9Ot9b-rbDEu1xDGgdaIe8uqT4y5YuN5P0aJOm7l1LgiA5fNcXMASdzcM0xZKJMKXrcd7Qo7dUdyAodD6hFnbQ5QNydvjh9P0w7boypAbWK0vtxFUu08I6kVnnXCVNph0EupOBkZZlfALTzw3zshK5Lbh3peUMmKwphM0Me0i2wzz4x4TKQjo-4LqUEAVybY3zJYSP0pemynOrE_IukoW6aBE4FGJixxTQDYWSVChJBZENZwnZ7SWnbAd4jn03ZqoJfEp59YbX6xv6kf7KeoCqEL1Qc2G-mKpOR1XF8ZhTeG-551nlNbhOlRMazCT4TVIk5BUqkkJTAi9mdVcRAR8HQbnUPoSHeA49AM6diBNMgI3ItFdFhSTMmwt-vloqBLvMwYlk_2BBQCEOnl5CHrXKu55VjmA_4MAkpIjUOpp2TAn11wajHOJ4IcrqyX9J8AW5OTwdHavjo5NPT8mtNnFDwjrdIduXi5V_Bv7gpXneLPWf5dtgeg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5BkSouiDcpBfaABAfcxN6HbTi1QNQCrRCiUsRltS-H0HQTxc2F38CPZsbehJgCF25WZuz1Zh474535lpCnEKMaWwxsooVkCWeaJ6YyRcK48DpPbV54_A55fCIPT_m7kRhFSCHshTHn9leZ795mC_q08dtwYc_6c1e15l7IfgruNYFFaoQehbOr5FouRI42-ungy3pDAc-gbxqNInNE-fnDA37rfJ92FqwG1_-y995YvrqllRtr1fAmuRGDTLrfasUtcsWH22T7OG6j3yE_8IjeZBK-NXVYgTo_nSwmy_N-7dsjlugKyIBOAo3QqzXFb7a03qzSo02dunctCbLk8F3PYQg6nYVxgj0TYUzX47ygRy-pjigodFZRC0tofZecDt9-fn2YxGMZEgMGyxJbudKlWlgnUuucK6VJtYNMtxoYaVnKK5h-ZpiXpchszr0rLGfAZE0ubGrYPbIVZsE_IFTm0vEB14WENJBra5wvIH-UvjBlllndI686slDzFoJDISh2lwLKoVCSCiWpILXhrEf2VpJTNiKe48EbU9VkPoW8fMPz9Q2rkf7KeoCq0Hmh5ofZYqyi0auS4z6n8N5yz9PSa4idSic0-EkInKTokWeoSAp9CSq2ji0R8OcgKpfah_wQN6IHwLnb4QQfYDtkulJFhSQsnAt-tqwVol1mEEWyf7AgohCHUK9H7rfKu55Vhmg_EMH0SN5R6860u5Qw-dqAlEMiL0RR7vyXBJ-Q7Y9vhurD0cn7h-R6W7ghwUx3ydbFYukfQTx4YR43lv4TPe5gRQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Post-injection+delirium%2Fsedation+syndrome+in+patients+with+schizophrenia+treated+with+olanzapine+long-acting+injection%2C+I%3A+analysis+of+cases&rft.jtitle=BMC+psychiatry&rft.au=Detke%2C+Holland+C&rft.au=McDonnell%2C+David+P&rft.au=Brunner%2C+Elizabeth&rft.au=Zhao%2C+Fangyi&rft.date=2010-06-10&rft.pub=BioMed+Central+Ltd&rft.issn=1471-244X&rft.eissn=1471-244X&rft.volume=10&rft.spage=43&rft_id=info:doi/10.1186%2F1471-244X-10-43&rft.externalDocID=A230287005 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-244X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-244X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-244X&client=summon |